1-12 of 12 results for subject:Patients
Librarians' tools
- Search time
- 0.183 seconds
- Solr query time
- 0.003 seconds
- Search query
- subject:Patients
- We searched for
- subject_t:Patients OR subject_t:"Sick people" OR subject_ses:92375
Type
House
Session
Month
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
More
National Institute for Clinical Excellence (12)
Publisher
Type
Select Committee reports (Government responses);
Command papers
Author
Department of Trade and Industry; Department of Health
Laid on
17 November 2000
Notes
Received 17.11.00
Subjects
Cancer; Diagnosis; Complementary medicine; Finance; Genetics; Drugs; Equipment; NHS; Medical treatments; Patients; Staff; Registration; Standards; Screening; Surgery; Research; Science and Technology Committee; National Institute for Clinical Excellence; Radiotherapy; Association of the British Pharmaceutical Industry; Medical Research Council; Clinical trials; Cancer Research Funding Forum
Date
17 November 2000
Reference
Cm 4928
House
House of Commons
Supplementary on patient representation on National Institute for Clinical Excellence and that account should be taken of improvement in quality of life as well as abatement of symptons.
Supplementary on patient representation on National Institute for Clinical Excellence and that account should be taken of improvement in quality of life as well as abatement of symptons.
Asked by
Phyllis Starkey
(Labour)
Answering body
Department of Health
Oral questions - 1st Supplementary
Status
Answered
Answered on
4 July 2000
Subjects
Drugs; Patients; National Institute for Clinical Excellence
Date
4 July 2000
Reference
353 c159-60
Chamber / Committee
House of Commons chamber
House
House of Commons
Answered by
John Denham
(Labour)
Answering body
Department of Health
Type
Oral answers to questions
Subjects
Drugs; Patients; National Institute for Clinical Excellence
Date
4 July 2000
Reference
353 c158-9
Chamber / Committee
House of Commons chamber
House
House of Commons
To ask the Secretary of State for Health, if he will ask the National Institute for Clincial Excellence to hear oral evidence from multiple sclerosis patients; what guidance he has given to the National Institute for Clincial Excellence about taking evidence from patients.
To ask the Secretary of State for Health, if he will ask the National Institute for Clincial Excellence to hear oral evidence from multiple sclerosis patients; what guidance he has given to the National Institute for Clincial Excellence about taking evidence from patients.
Asked by
David Lidington
(Conservative)
Answered by
John Denham
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
29 June 2000
For answer on
4 July 2000
Answered on
4 July 2000
Mr. Lidington: To ask the Secretary of State for Health (1) if he will ask the National Institute for Clinical Excellence to hear
oral evidence from multiple sclerosis patients; [129116]
(2) what guidance he has given to the National Institute for Clinical Excellence about taking evidence from patients. [129117]
Mr. Denham: The National Institute for Clinical Excellence (NICE) determines its own processes, within broad guidance from Ministers
set out in a "Memorandum of Understanding" of August 1999. We have asked NICE to follow a transparent and well-structured process
for its appraisals, giving appropriate interested parties the opportunity to submit evidence, to comment on draft conclusions, and
to appeal to a panel independent of those involved in the original judgment. For their appraisal of beta interferon NICE have sought
evidence from patient representative organisations and we anticipate that NICE will be well aware from this of the views of
individual multiple sclerosis patients.
Subjects
Evidence; NHS; Patients; Multiple sclerosis; National Institute for Clinical Excellence; Interferon beta
Date
4 July 2000
Reference
353 c148W; 129116;129117
House
House of Commons
Answered by
John Denham
(Labour)
Asked by
John Bercow
(Conservative)
Answering body
Department of Health
Type
Oral answers to questions
To ask the Secretary of State for Health, What action he is taking to ensure that patients are represented during the deliberations of the National Institute for Clinical Excellence.
Subjects
Drugs; Patients; National Institute for Clinical Excellence
Date
4 July 2000
Reference
353 c158-9
Chamber / Committee
House of Commons chamber
House
House of Commons
1st supplementary on assessment of beta interferon and disclosure of findings.
1st supplementary on assessment of beta interferon and disclosure of findings.
Asked by
John Bercow
(Conservative)
Answering body
Department of Health
Oral questions - 1st Supplementary
Status
Answered
Answered on
4 July 2000
Subjects
Drugs; Patients; National Institute for Clinical Excellence
Date
4 July 2000
Reference
353 c158-9
Chamber / Committee
House of Commons chamber
House
House of Commons
Answered by
John Denham
(Labour)
Answering body
Department of Health
Type
Oral answers to questions
Subjects
Drugs; Patients; National Institute for Clinical Excellence
Date
4 July 2000
Reference
353 c159-60
Chamber / Committee
House of Commons chamber
House
House of Commons
To ask the Secretary of State for Health, What action he is taking to ensure that patients are represented during the deliberations of the National Institute for Clinical Excellence.
To ask the Secretary of State for Health, What action he is taking to ensure that patients are represented during the deliberations of the National Institute for Clinical Excellence.
Asked by
John Bercow
(Conservative)
Answered by
John Denham
(Labour)
Answering body
Department of Health
Oral questions - Lead
Status
Answered
Tabled on
20 June 2000
For answer on
4 July 2000
Answered on
4 July 2000
Subjects
Drugs; Patients; National Institute for Clinical Excellence
Date
4 July 2000
Reference
353 c158-9; 127523
Chamber / Committee
House of Commons chamber
House
House of Commons
Answered by
Lord Hunt of Kings Heath
(Labour)
Type
Oral answers to questions
Subjects
Costs; Drugs; NHS; Medical treatments; Patients; Prescriptions; National Institute for Clinical Excellence
Date
15 March 2000
Reference
610 c1537-8
Chamber / Committee
House of Lords chamber
House
House of Lords
1st supplementary on making sure patients do not have costly treatments taken away when the National Institute for Clinical Excellence advises on treatments.
1st supplementary on making sure patients do not have costly treatments taken away when the National Institute for Clinical Excellence advises on treatments.
Asked by
Baroness Gardner of Parkes
(Conservative)
Oral questions - 1st Supplementary
Status
Answered
Answered on
15 March 2000
Subjects
Costs; Drugs; NHS; Medical treatments; Patients; Prescriptions; National Institute for Clinical Excellence
Date
15 March 2000
Reference
610 c1537-8
Chamber / Committee
House of Lords chamber
House
House of Lords
How they intend to ensure that those patients currently receiving beneficial National Health Service treatments or drug therapies will not be disadvantaged when discriminatory postcode prescribing is abolished.
How they intend to ensure that those patients currently receiving beneficial National Health Service treatments or drug therapies will not be disadvantaged when discriminatory postcode prescribing is abolished.
Asked by
Baroness Gardner of Parkes
(Conservative)
Answered by
Lord Hunt of Kings Heath
(Labour)
Oral questions - Lead
Status
Answered
For answer on
15 March 2000
Answered on
15 March 2000
Subjects
Costs; Drugs; NHS; Medical treatments; Patients; Prescriptions; National Institute for Clinical Excellence
Date
15 March 2000
Reference
610 c1537-8
Chamber / Committee
House of Lords chamber
House
House of Lords
Answered by
Lord Hunt of Kings Heath
(Labour)
Asked by
Baroness Gardner of Parkes
(Conservative)
Type
Oral answers to questions
How they intend to ensure that those patients currently receiving beneficial National Health Service treatments or drug therapies will not be disadvantaged when discriminatory postcode prescribing is abolished.
Subjects
Costs; Drugs; NHS; Medical treatments; Patients; Prescriptions; National Institute for Clinical Excellence
Date
15 March 2000
Reference
610 c1537-8
Chamber / Committee
House of Lords chamber
House
House of Lords